PAMP
RVNC

Polar Asset Management Partners’s Revance Therapeutics, Inc. RVNC Stock Holding History

Polar Asset Management Partners’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-90,000
Closed -$467K – 847
2024
Q3 		$467K Buy
+90,000
New +$447K 0.01% 466

Other funds holding RVNC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Polar Asset Management Partners's RVNC Position: Q4 2024 in Review

Polar Asset Management Partners sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 90,000 shares — an estimated $467K sold.

Polar Asset Management Partners first reported a position in RVNC in Q3 2024 and held it in 1 quarter. The position peaked at $467K in Q3 2024. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

  • Polar Asset Management Partners reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
  • Polar Asset Management Partners sold 90,000 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $467K.
  • Polar Asset Management Partners first reported a position in Revance Therapeutics, Inc. in Q3 2024 and held it in 1 quarter.
  • Polar Asset Management Partners's Revance Therapeutics, Inc. position peaked at $467K in Q3 2024.
  • 173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Polar Asset Management Partners's 13F filing for Q4 2024, filed 14 Feb 2025.